Form 4: Brainstorm Cell Therapeutics CEO Acquires Shares in Recent Transaction

Chaim Lebovits, CEO of Brainstorm Cell Therapeutics, recently acquired 135,000 shares of common stock at an average price of $0.3753 per share.

Summary

• On May 6, 2024, Chaim Lebovits, the President and CEO of Brainstorm Cell Therapeutics Inc., acquired 135,000 shares of the company's common stock.
• The shares were purchased at a weighted average price of $0.3753, with individual transaction prices ranging from $0.3498 to $0.399.
• Following the transaction, Lebovits directly owns 993,565 shares of common stock.
• Lebovits may also be deemed the beneficial owner of 2,000,847 indirectly held shares, including 1,933,794 shares owned by ACCBT Corp. and 67,053 shares owned by ACC International Holdings Ltd.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The CEO's purchase of shares is generally seen as a positive sign, but the filing itself is a routine disclosure.

Positives

• The CEO's purchase of shares could be interpreted as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common in publicly traded companies. The market may interpret this as a sign of confidence from the CEO.

Stakeholder Impact

• Shareholders may view the CEO's stock purchase as a positive indicator of the company's prospects.

Key Dates

Keywords

Brainstorm Cell Therapeutics, BCLI, Chaim Lebovits, SEC Form 4, Stock Acquisition, Beneficial Ownership, Insider Trading